- This new research adds to prior research which indicates that NSM is not associated with increased risk of recurrence.
- This study did not include patient reported outcomes and satisfaction with NSM.
- The researchers are extending this study to allow for a longer follow-up period to better estimate the risk of recurrence after NSM.
Scientific Strength: Medium-High
- This is a well done study on the risk of recurrence in early stage breast cancer patients who opt for NSM.
- The follow-up period is long enough to exclude early recurrences with aggressive breast cancer types. However, the follow-up period may not be long enough to determine risk of recurrence for patients with hormone receptor-positive early-stage breast cancers for which risk of recurrence is already low.
- This study only followed patients from one institution. There may be variables not accounted for in this study that would impact results from other institutions.
- The authors recognize there may have been a selection bias and that NSM may have been offered disproportionately to patients who had a good prognosis. Although Massachusetts General no longer bases their recommendations for NSM on tumor size, receptor status or stage, these factors may have influenced recommendations during the study period.
Research Timeline: Post-approval
- This technically is currently used in the clinic now.